A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients

NCT06028932 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Ovarian Carcinoma

Interventions

DRUG: Sacituzumab govitecan

Sponsor

Yale University

Collaborators

[object Object]